Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia
© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine..
BACKGROUND: The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs.
HYPOTHESIS/OBJECTIVES: The objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4-week time period.
ANIMALS: Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent.
METHODS: This study was a prospective, 1-armed open-label trial. Physical examination, complete blood count, chemistry panel, and owner-assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre-enrollment and week 4.
RESULTS: Fourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL-1 , P < .004). On quality of life surveys, pet owners perceived their dog appeared to be panting less (P < .002) and that the general health improved (P < .03). Four dogs had a change in coat pigmentation. The peak plasma concentration of TCMCB07 in cachectic dogs was similar to that in healthy beagle dogs.
CONCLUSIONS AND CLINICAL IMPORTANCE: TCMCB07 was safe and has potential efficacy in pet dogs with cachexia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of veterinary internal medicine - 37(2023), 6 vom: 28. Nov., Seite 2344-2355 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Axiak-Bechtel, Sandra M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anorexia |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvim.16915 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363893237 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363893237 | ||
| 003 | DE-627 | ||
| 005 | 20240210232825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvim.16915 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM363893237 | ||
| 035 | |a (NLM)37897303 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Axiak-Bechtel, Sandra M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. | ||
| 520 | |a BACKGROUND: The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs | ||
| 520 | |a HYPOTHESIS/OBJECTIVES: The objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4-week time period | ||
| 520 | |a ANIMALS: Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent | ||
| 520 | |a METHODS: This study was a prospective, 1-armed open-label trial. Physical examination, complete blood count, chemistry panel, and owner-assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre-enrollment and week 4 | ||
| 520 | |a RESULTS: Fourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL-1 , P < .004). On quality of life surveys, pet owners perceived their dog appeared to be panting less (P < .002) and that the general health improved (P < .03). Four dogs had a change in coat pigmentation. The peak plasma concentration of TCMCB07 in cachectic dogs was similar to that in healthy beagle dogs | ||
| 520 | |a CONCLUSIONS AND CLINICAL IMPORTANCE: TCMCB07 was safe and has potential efficacy in pet dogs with cachexia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anorexia | |
| 650 | 4 | |a canine | |
| 650 | 4 | |a emaciation | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Melanocortins |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Leach, Stacey B |e verfasserin |4 aut | |
| 700 | 1 | |a Newton-Northup, Jessica R |e verfasserin |4 aut | |
| 700 | 1 | |a Milner, Rowan J |e verfasserin |4 aut | |
| 700 | 1 | |a Fox-Alvarez, Stacey A |e verfasserin |4 aut | |
| 700 | 1 | |a Fagman, Lana I |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Kaylee A |e verfasserin |4 aut | |
| 700 | 1 | |a Tate, Deborah J |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Zachary M |e verfasserin |4 aut | |
| 700 | 1 | |a Chretin, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Justin W |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimoto, Sean K |e verfasserin |4 aut | |
| 700 | 1 | |a Selting, Kimberly A |e verfasserin |4 aut | |
| 700 | 1 | |a Flesner, Brian K |e verfasserin |4 aut | |
| 700 | 1 | |a White, Carrie R |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Aherne, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bergman, Philip J |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, LeAnn |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, Kenneth A |e verfasserin |4 aut | |
| 700 | 1 | |a Callahan, Michael F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of veterinary internal medicine |d 1996 |g 37(2023), 6 vom: 28. Nov., Seite 2344-2355 |w (DE-627)NLM012980854 |x 1939-1676 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:6 |g day:28 |g month:11 |g pages:2344-2355 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvim.16915 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 6 |b 28 |c 11 |h 2344-2355 | ||